Kiromic BioPharma Stock Plunges After $40M Equity Raise Issued At 24% Discount

  • Kiromic BioPharma Inc KRBP has priced an underwritten public offering of 8 million shares at $5.00 per share, for gross proceeds of $40 million.
  • The offer price is at a 24% discount on the last close price of $6.57 on Tuesday.
  • Underwriters have an option to purchase up to an additional 1.2 million shares.
  • The offering will close by July 2.
  • ThinkEquity, a Fordham Financial Management division, is acting as the sole book-running manager for the offering.
  • The proceeds will be used for ALEXIS-ISO-1 and ALEXIS-PRO-1 product candidates, working capital, and general corporate purposes.
  • In May, the company submitted an Investigational New Drug to the FDA for Phase 1 trial for CAR T-Cell therapy for any solid malignancy expressing Iso-mesothelin. Pending FDA authorization, dosing will start in Q3 of 2021.
  • Price Action: KRBP shares are down 28% at $4.78 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingOfferingsFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!